Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5553346 | 0.94 | P2RX7 (0.60) | P2RX7ABCB11 | |
| SCHEMBL7083974 | 0.92 | P2RX7 (0.50) | P2RX7 | |
| SCHEMBL4126837 | 0.89 | P2RX7 (0.67) | P2RX7ABCB11 | |
| SCHEMBL7085709 | 0.89 | P2RX7 (0.64) | P2RX7ABCB11 | |
| SCHEMBL7083528 | 0.88 | P2RX7 (0.63) | P2RX7ABCB11 | |
| SCHEMBL7077646 | 0.86 | P2RX7 (0.63) | P2RX7ABCB11 | |
| SCHEMBL5557788 | 0.86 | P2RX7 (0.51) | P2RX7 | |
| SCHEMBL7077648 | 0.85 | P2RX7 (0.66) | P2RX7ABCB11 | |
| SCHEMBL7079398 | 0.85 | P2RX7 (0.58) | P2RX7ABCB11 | |
| SCHEMBL7085513 | 0.84 | P2RX7 (0.65) | P2RX7ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1906960-A1 | NEW COMBINATION 1 | AstraZeneca AB (SE) | 2008-04-09 | — | — | EP | claimed |
| JP-2007501270-A | — | — | 2007-01-25 | — | — | JP | claimed |
| WO-2007008155-A1 | NEW COMBINATION 1 | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| WO-2006083214-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 RECEPTOR ANTAGONIST AND A HMG-COA REDUCTASE INHIBITOR | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | claimed |
| EP-1644042-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING A P2X7 RECEPTOR ANTAGONIST AND METHOTREXATE | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | claimed |
| EP-1633401-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR ALPHA | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | claimed |
| WO-2004105796-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING A P2X7 RECEPTOR ANTAGONIST AND METHOTREXATE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | claimed |
| WO-2004105798-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | claimed |
| US-20030013704-A1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | claimed |
| WO-2009019503-A2 | P2X7 ANTAGONISTS FOR USE IN THE TREATMENT OF MOOD DISORDERS | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | WO | disclosed |
| EP-1644042-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING A P2X7 RECEPTOR ANTAGONIST AND METHOTREXATE | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1644041-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 ANTAGONIST AND SULFASALAZINE | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1633401-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR ALPHA | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105797-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 ANTAGONIST AND SULFASALAZINE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004105796-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING A P2X7 RECEPTOR ANTAGONIST AND METHOTREXATE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004105798-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
| US-20030013704-A1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| EP-1242364-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044170-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013704-A1 | Adamantane derivatives | ADRA2C, CHRNA2, ADRA1D | P2RX7 1500/4885ABCB11 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.